| Systematic (IUPAC) name | |
|---|---|
| (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4- (diaminomethylideneamino)-2-hydroxy-cyclopentane- 1-carboxylic acid | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Pharmacokinetic data | |
| Bioavailability | 100% (IV) |
| Half-life | 7.7 to 20.8 hour in patients with normal renal function |
| Excretion | renal |
| Identifiers | |
| CAS number | 229614-55-5 |
| ATC code | None |
| PubChem | CID 151164 |
| ChemSpider | 133234 |
| UNII | 9ZS94HQO3B |
| ChEMBL | CHEMBL332608 |
| Chemical data | |
| Formula | C15H28N4O4 |
| Mol. mass | 328.40722 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
| Influenza (Flu) |
|---|
| Types |
| Vaccines |
| Treatment |
| Pandemics |
| Outbreaks |
| See also |
Peramivir is an experimental antiviral drug developed by BioCryst Pharmaceuticals for the treatment of influenza. It has been authorized for the emergency use of treatment of certain hospitalized patients with known or suspected 2009 H1N1 influenza.[1]
Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells.
The development of peramivir is supported by the US Department of Health and Human Services as part of the US government's effort to prepare against the threat of an influenza pandemic.[2]
Peramivir is already available in Japan as RAPIACTA (R) and also available in South Korea as PERAMIFLU. Peramivir is currently the only intravenous option for treating swine flu. The drug is in Phase III studies in US.[3][4]
Contents |
In October 2009, it was reported that the experimental antiviral drug peramivir had been effective in treating serious cases of swine flu.[5] On October 23, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization for Peramivir, allowing the use of the drug in intravenous form for hospitalized patients only in cases where the other available methods of treatment are ineffective or unavailable;[6] for instance, if oseltamivir (Tamiflu) resistance develops and a person is unable to take Relenza via the inhaled route. The Emergency Use Authorization expired on June 23, 2010.
Biocryst also donated 1200 courses of treatment to the US department of Health and Human Services.[7]
According to a research report published in June 2011, a novel variant of swine flu has emerged in Asia with a genetic adaptation giving some resistance to Roche's (ROG.VX) Tamiflu and GlaxoSmithKline's (GSK.L) Relenza, the two mainstay drugs used to tackle the disease. There was no significant reduction in sensitivity to Peramivir. [8]
Initial treatment courses are for 5 to 10 days duration. Treatment beyond 10 days is permitted depending on clinical presentation such as critical illness (e.g., respiratory failure or intensive care unit admission), continued viral shedding or unresolved clinical influenza illness.[9]
|
||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||